Schwarz Christopher G, Gunter Jeffrey L, Wiste Heather J, Przybelski Scott A, Weigand Stephen D, Ward Chadwick P, Senjem Matthew L, Vemuri Prashanthi, Murray Melissa E, Dickson Dennis W, Parisi Joseph E, Kantarci Kejal, Weiner Michael W, Petersen Ronald C, Jack Clifford R
Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.
Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA; Department of Information Technology, Mayo Clinic and Foundation, Rochester, MN, USA.
Neuroimage Clin. 2016 May 30;11:802-812. doi: 10.1016/j.nicl.2016.05.017. eCollection 2016.
Alzheimer's disease (AD) researchers commonly use MRI as a quantitative measure of disease severity. Historically, hippocampal volume has been favored. Recently, "AD signature" measurements of gray matter (GM) volumes or cortical thicknesses have gained attention. Here, we systematically evaluate multiple thickness- and volume-based candidate-methods side-by-side, built using the popular FreeSurfer, SPM, and ANTs packages, according to the following criteria: (a) ability to separate clinically normal individuals from those with AD; (b) (extent of) correlation with head size, a nuisance covariatel (c) reliability on repeated scans; and (d) correlation with Braak neurofibrillary tangle stage in a group with autopsy. We show that volume- and thickness-based measures generally perform similarly for separating clinically normal from AD populations, and in correlation with Braak neurofibrillary tangle stage at autopsy. Volume-based measures are generally more reliable than thickness measures. As expected, volume measures are highly correlated with head size, while thickness measures are generally not. Because approaches to statistically correcting volumes for head size vary and may be inadequate to deal with this underlying confound, and because our goal is to determine a measure which can be used to examine age and sex effects in a cohort across a large age range, we thus recommend thickness-based measures. Ultimately, based on these criteria and additional practical considerations of run-time and failure rates, we recommend an AD signature measure formed from a composite of thickness measurements in the entorhinal, fusiform, parahippocampal, mid-temporal, inferior-temporal, and angular gyrus ROIs using ANTs with input segmentations from SPM12.
阿尔茨海默病(AD)研究人员通常将磁共振成像(MRI)用作疾病严重程度的定量指标。从历史上看,海马体体积一直是人们青睐的指标。最近,基于灰质(GM)体积或皮质厚度的“AD特征”测量受到了关注。在这里,我们根据以下标准,系统地并行评估了多种基于厚度和体积的候选方法,这些方法是使用流行的FreeSurfer、SPM和ANTs软件包构建的:(a)将临床正常个体与AD患者区分开来的能力;(b)与头部大小(一个令人讨厌的协变量)的(相关程度)相关性;(c)重复扫描的可靠性;以及(d)在一组有尸检的人群中与Braak神经原纤维缠结阶段的相关性。我们表明,基于体积和厚度的测量方法在区分临床正常人群和AD人群以及与尸检时的Braak神经原纤维缠结阶段的相关性方面通常表现相似。基于体积的测量方法通常比基于厚度的测量方法更可靠。正如预期的那样,体积测量与头部大小高度相关,而厚度测量通常并非如此。由于针对头部大小对体积进行统计校正的方法各不相同,可能不足以处理这种潜在的混杂因素,并且由于我们的目标是确定一种可用于检查大年龄范围内队列中的年龄和性别效应的测量方法,因此我们推荐基于厚度的测量方法。最终,基于这些标准以及运行时间和失败率等其他实际考虑因素,我们推荐一种AD特征测量方法,该方法由内嗅皮质、梭状回、海马旁回、颞中回、颞下回和角回感兴趣区域(ROI)的厚度测量值组合而成,使用ANTs并输入来自SPM12的分割结果。